US Cancer Clinics Rush to Access Revolutionary Pancreatic Cancer Drug Daraxonrasib

Across the US, cancer clinics have been thrown into a frenzy after the Food and Drug Administration authorized an expanded access program for Revolution Medicines (NASDAQ: RVMD)' experimental drug daraxonrasib, aimed at pancreatic cancer.

The pharmaceutical company announced clinical trial results showing that daraxonrasib, a once-daily oral medication, approximately doubled median survival in patients with advanced pancreatic adenocarcinoma, improving it from 6.7 to 13.2 months compared to standard chemotherapy treatments.

FDA's clearance for compassionate use came less than three weeks after those results were shared publicly, allowing patients previously treated for metastatic pancreatic cancer to get free access through selected cancer centers. This swift action reflects the severe unmet need in this disease, which claims around 53,000 lives annually in the US alone.

Dr. Daniel King from the Zuckerberg Cancer Center noted an overwhelming influx of patient inquiries and referrals following the FDA announcement, with oncologists working hard to open protocols to offer the drug under this expanded program.

But putting this access into motion is anything but straightforward. Physicians must submit detailed requests for each patient to Revolution Medicines for approval, and those cases then undergo FDA oversight. Institutional review boards have to monitor treatment, which adds layers of paperwork and resource strains amid already busy oncology clinics.

Mark Goldsmith, CEO of Revolution Medicines, highlighted ongoing efforts to complete regulatory filings, though he stopped short of providing a timeline for full FDA approval or patient numbers expected to join the early access program.

Meanwhile, high-profile patients, including former Senator Ben Sasse who disclosed his Stage 4 pancreatic cancer diagnosis, have publicly shared their involvement with daraxonrasib, further amplifying public attention.

Experts like Dr. Gulam Manji from Columbia/NewYork-Presbyterian have called the drug a significant step forward - "not a cure but a breakthrough to build on" - given how few advancements have doubled survival rates for such a grim disease in recent memory.

The true test will be how quickly the FDA processes the inevitable surge in requests amid maintaining safety oversight. How clinics navigate administrative hurdles and balance demand with supply could set a precedent for future expanded access scenarios in oncology.